Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

13M

53M

Müük

19M

730M

P/E

Sektori keskmine

75.292

47.946

Aktsiakasum

1.41

Dividenditootlus

0.18

Kasumimarginaal

7.329

Töötajad

11,000

EBITDA

8.8M

189M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-12.93% downside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.18%

2.27%

Järgmine tulemuste avaldamine

3. nov 2026

Järgmine dividendimakse kuupäev

13. nov 2026

Järgmine aktsia dividendi kuupäev (ex-date)

23. okt 2026

Turustatistika

By TradingEconomics

Turukapital

4.7B

18B

Eelmine avamishind

0

Eelmine sulgemishind

0

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2026, 20:06 UTC

Revvity Inc shares are declining, having pulled back from earlier gains amid a broader market trend lower since Wednesday's close.

7. okt 2026, 19:25 UTC

News

Barclays raised Revvity Inc's price target to $160.00 from $115.00, maintaining an Equal-weight rating, as the stock trades modestly higher.

6. okt 2026, 22:41 UTC

News

Revvity Inc shares declined in after-market trading despite an Outperform rating from William Blair, closing at their lowest point since Tuesday.

5. okt 2026, 19:21 UTC

Correlated Moves

Revvity Inc is advancing, likely influenced by a significant rise in shares of Charles River Laboratories, reaching its best cumulative return since Friday's close.

2. okt 2026, 19:45 UTC

News

Revvity Inc. will release Q3 2026 financial results on November 3, 2026, contributing to the stock's upward movement today, despite a slight retracement.

1. okt 2026, 20:03 UTC

Revvity Inc shares fell sharply from an early peak, currently trading near their lowest point of the day despite being above the 20-day moving average.

30. sept 2026, 21:02 UTC

Revvity Inc is trading modestly higher in after-market hours, significantly above its 20-day moving average and near the upper end of its one-month range.

29. sept 2026, 19:36 UTC

Revvity Inc is trading higher, reaching a peak return since Monday's close and maintaining a position above its 20-day moving average.

28. sept 2026, 20:20 UTC

Revvity Inc's shares are trading modestly lower in after-market hours, shifting from a slight gain to a loss since Monday's close.

25. sept 2026, 20:01 UTC

Revvity Inc shares fell sharply, pulling back from earlier gains and currently trading below Thursday's close despite being above its 20-day moving average.

24. sept 2026, 23:11 UTC

Revvity Inc has advanced modestly in after-market trading, remaining significantly above its 20-day moving average and showing notable gains over the past month.

23. sept 2026, 20:07 UTC

Revvity Inc shares fell sharply, settling below Tuesday's close after an early peak, though remaining above the 20-day moving average.

22. sept 2026, 19:31 UTC

Revvity Inc shares fell sharply after briefly gaining earlier, but remain above their 20-day moving average and near the upper end of their one-month range.

21. sept 2026, 23:56 UTC

Revvity Inc is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month range.

16. sept 2026, 20:07 UTC

Revvity Inc is trading higher, continuing a strong momentum with four consecutive sessions of gains and remaining well above its 20-day moving average.

15. sept 2026, 22:02 UTC

Revvity Inc. shares are lower in after-market trading, reflecting broader market trends amid economic concerns following a significant drop in the NY Empire State Manufacturing Index.

14. sept 2026, 20:08 UTC

Revvity Inc shares are higher in Monday's session, continuing a broader upward trend since Friday. The stock is above its 20-day moving average.

11. sept 2026, 20:08 UTC

News

Revvity Inc will acquire Human Cell Design to enhance its Life Sciences sector reach. Shares are rising today after five consecutive lower sessions.

9. sept 2026, 20:07 UTC

News
Event

Revvity Inc announced its acquisition of Human Cell Design to enhance its Life Sciences portfolio. Shares are trading lower amid broader market weakness.

8. sept 2026, 20:07 UTC

Revvity Inc shares are lower today, continuing a decline since Friday's close. The stock opened down and remained weak throughout the session.

4. sept 2026, 19:47 UTC

News

Revvity Inc shares are lower amid mixed analyst ratings and price target adjustments. Earlier, shares pulled back from a session high during ongoing market volatility.

3. sept 2026, 20:07 UTC

News

Revvity Inc shares are lower today, reaching a low of -2.18%. Analyst Catherine Ramsey Schulte raised the price target to $144.00 from $131.00.

2. sept 2026, 21:02 UTC

Revvity Inc shares are higher in after-market trading, with no specific news identified. The broader market context includes a disappointing ADP employment report.

1. sept 2026, 19:43 UTC

News

Revvity shares are lower as RBC Capital initiates coverage with a Sector Perform rating and a price target of $135.

31. aug 2026, 20:07 UTC

Revvity Inc shares are lower amid broader market reactions to inflation comments from Warsh at the Jackson Hole Economic Symposium.

28. aug 2026, 22:51 UTC

Revvity Inc shares are trading lower in after-market hours. No specific news was identified to explain this movement amid overall weak market performance.

27. aug 2026, 20:07 UTC

Revvity Inc shares are higher, continuing a trend of gains since Wednesday. The stock remains above its 20-day moving average with four consecutive higher closes.

26. aug 2026, 19:16 UTC

Revvity Inc shares are higher, supported by strong performance metrics and trading above the 20-day moving average. No specific news was identified for this move.

25. aug 2026, 21:02 UTC

Revvity Inc. shares are trading lower in after-market hours, despite remaining above their 20-day moving average and near the upper end of their one-month range.

24. aug 2026, 19:56 UTC

Revvity Inc. shares are lower today, having reached a session low earlier. Broader market pressures include economic concerns related to U.S.-Iran relations.

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

-12.93% langus

12 kuu keskmine prognoos

Keskmine 134.25 USD  -12.93%

Kõrge 165 USD

Madal 110 USD

Põhineb 15 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

5

Osta

10

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.